

vol.1 no.1

Life Sciences Discovery Fund Update

The Life Sciences Discovery Fund has embarked on a journey of scientific progress and promise. There has been very strong interest in the Fund and its activities. With \$1 million from Washington State operations dollars, nearly \$6 million in private donor monies and \$32 million from the tobacco settlement agreement, the Fund continues to attract diverse civic support from across the State. The organizational development of the Life Sciences Discovery Fund has steadily evolved since its inception — read on about the Fund's grant competitions, award portfolio, and anticipated pathways to impact.

Grant Competitions Designed and Launched

- Four grant competitions: 3 are complete; 1 will be complete in December, 2008
- Very strong statewide interest: 264 proposals submitted to date
- Three-fourths of proposals received have multi-institutional partnerships
- One-half of proposals received have corporate partnerships
- 9 Washington counties represented in pool of proposal submissions
- Scientific review by national experts

17 Innovative Awards

- Totaling more than \$31 million
- 8 different lead institutions, each collaborating with at least one other organization
- One-third have Eastern-Western Washington collaborations
- Research foci:
 - Autoimmune diseases (lupus, MS, Type 1 diabetes)
 - Cancer (breast, prostate, solid tumors)
 - Cardiovascular disease (heart attack, tissue calcification)
 - Early learning
 - Independent living

- Liver fibrosis (proteomics platform)
- Medical genetics/genomics
- Medication management
- Neurological disorders (epilepsy, stroke, traumatic brain injury)
- Pain localization
- Surgical best practices
- Areas of disease care — each of the 17 awards touch upon at least one aspect along the disease care continuum:
 - Prevention
 - Screening
 - Diagnosis
 - Treatment
 - Palliative or end-of-life care/recovery

On Track for Impact

- Potential economic impact of 17 awards:
 - 13 with potential for commercial product development or company formation
 - 3 with potential health-care cost-savings or increases in cost-effectiveness
 - 5 with potential for infrastructure and resource development
 - All show potential for enhancing the state's life sciences workforce
 - All show potential for attracting follow-on funding from public and private sources

Life Sciences

DISCOVERY FUND


LifeSciencesDiscoveryFund.org

- Examples of statewide impact:

Diabetes Evaluation in Washington State

Pacific Northwest Diabetes Research Institute

*Anticipated Impact:
Reduction in costs
and crises for
individuals and
families living with
Type 1 diabetes*



Surgical Care and Outcomes Assessment Program

University of Washington

*Anticipated Impact:
Widespread adoption
of best surgical
practices to prevent
unnecessary procedures
and mistakes*



Program for Autoimmune Disease Intervention

Benaroya Research Institute at Virginia Mason

*Anticipated Impact:
Improved targeted
therapies for
treatment of
autoimmune diseases*



- Examples of public-private enterprise through collaboration:

Existing private companies

Swedish Neuroscience Institute neurosurgeons lead by Dr. David Newell, are working with EKOS, a Bothell, Washington-based biomedical company, to provide stroke victims with a potentially superior treatment to reduce associated health problems and disabilities using a combination of ultrasound-enhanced drug delivery and advanced imaging.

Potential for start-up firms

The University of Washington's Dr. Pierre Mourad is testing an ultrasound device for its ability to localize deep pain. The value added to the technology through the Life Sciences Discovery Fund's grant award will hopefully increase the competitiveness of the start-up company, PhysioSonics, for SBIR and investment funding.

Engagement of larger corporations

Life Sciences Discovery Fund awards can enhance infrastructure development for commercialization of promising new technologies. This creates a research capacity that can be utilized by multiple projects, including those involving corporate entities. One such Fund award is the phase 1 clinical trial unit at the Fred Hutchinson Cancer Research Center. It will provide an essential capability for early human drug trials with the power to facilitate commercialization of academic discoveries and to assist local companies developing new anti-cancer agents.

These examples highlight the Fund's role in stimulating innovation to improve health for Washingtonians, generate economic vitality in the state, and keep Washington's life sciences sector vibrant. Continue to follow along in support of the Life Sciences Discovery Fund as its story unfolds.